These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961 [TBL] [Abstract][Full Text] [Related]
5. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Rizk B; Aboulghar M; Smitz J; Ron-El R Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101 [TBL] [Abstract][Full Text] [Related]
6. Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol. Gaafar S; El-Gezary D; El Maghraby HA Reprod Biol; 2019 Jun; 19(2):145-148. PubMed ID: 31133458 [TBL] [Abstract][Full Text] [Related]
7. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966 [TBL] [Abstract][Full Text] [Related]
8. What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model? Atilgan R; Pala Ş; Yavuzkır Ş; Başpınar M; Yılmaz M; Ilhan N J Obstet Gynaecol; 2019 Jul; 39(5):687-694. PubMed ID: 30892121 [TBL] [Abstract][Full Text] [Related]
9. Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study. Torabizadeh A; Vahidroodsari F; Ghorbanpour Z Iran J Reprod Med; 2013 Oct; 11(10):837-42. PubMed ID: 24639705 [TBL] [Abstract][Full Text] [Related]
10. Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model. Hortu I; Karadadas E; Ozceltik G; Tavmergen E; Tavmergen Goker EN; Yigitturk G; Erbas O Arch Gynecol Obstet; 2021 Apr; 303(4):1099-1108. PubMed ID: 33140116 [TBL] [Abstract][Full Text] [Related]
11. How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists. Garcia-Velasco JA Reprod Biomed Online; 2009; 18 Suppl 2():71-5. PubMed ID: 19406035 [TBL] [Abstract][Full Text] [Related]
12. Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study. Kılıç N; Özdemir Ö; Başar HC; Demircan F; Ekmez F; Yücel O Avicenna J Med; 2015; 5(4):123-7. PubMed ID: 26629467 [TBL] [Abstract][Full Text] [Related]